Welcome to our dedicated page for Clene SEC filings (Ticker: CLNN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Clene's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Clene's regulatory disclosures and financial reporting.
Clene Inc. is updating its at-the-market stock offering program so it may sell up to $6,280,000 of common stock from time to time through Canaccord Genuity under an existing equity distribution agreement. The overall program allows sales of up to $25,000,000, but this supplement limits new potential sales to $6,280,000 because of Form S-3 public float restrictions and prior usage.
Clene has already sold shares of common stock with a maximum aggregate gross sales price of $3,706,213 under prior supplements and has sold $12.6 million of securities in total in the last 12 months under the same SEC size constraint. As of this supplement, the company’s public float is about $56.7 million, based on 8,812,826 non‑affiliate shares at $6.43 per share. Canaccord will act as sales agent on commercially reasonable efforts terms and earn up to 3.0% of the gross sales price per share as commission.
Clene Inc. files a preliminary shelf registration covering up to 491,496 shares of common stock for resale from time to time by existing selling securityholders. These shares may be issued upon conversion of 271,902 shares’ worth of 2024 Convertible Interest on senior secured convertible notes and 219,594 shares issuable upon conversion of additional 2025 senior secured convertible promissory notes. As of September 3, 2025, Clene had 10,030,386 shares of common stock outstanding. The company will not receive any proceeds from resale of these shares, though it has already received cash from issuing the notes.
Clene is a clinical-stage pharmaceutical company developing proprietary clean-surfaced nanocrystal (CSN®) therapeutics for neurodegenerative diseases including ALS, multiple sclerosis and Parkinson’s disease, and currently has no approved drugs and limited supplement revenue. The prospectus highlights FDA engagement on a potential accelerated approval pathway for ALS therapy CNM-Au8, ongoing and planned Phase 2/3 trials in ALS and MS, and notes recurring losses, low cash balances, covenant requirements under its 2024 notes and substantial doubt about its ability to continue as a going concern without additional financing.
Clene Inc. (CLNN) insider sale reported. General Resonance LLC reported a sale of 3,401 shares of Clene common stock on 08/21/2025 at a price of $5.34 per share, leaving beneficial ownership of 704,591 shares. The Form 4 was filed by one reporting person and signed by Heidi Ley.
Clene Inc. (CLNN) filed a Form 4 disclosing that director Vallerie McLaughlin was granted a stock option to buy 4,092 shares of common stock. The option has an exercise price of $3.60 per share, vests immediately, and covers 4,092 underlying shares. The option grant is exercisable through an expiration date of 08/13/2035. The transaction date reported is 08/14/2025. The filing indicates the Form 4 was submitted by one reporting person and was signed under power of attorney.
Clene Inc. (CLNN) reported a Section 16 Form 4 disclosing that director David J. Matlin was granted a stock option on 08/14/2025 for 7,255 shares of common stock under the companys Amended 2020 Stock Plan. The option has an exercise price of $3.60 per share, vests immediately upon grant, and is exercisable through an expiration date of 08/13/2035. Following the grant, Mr. Matlin beneficially owns 7,255 underlying shares via this option, held in a direct ownership form. The Form 4 was filed by one reporting person and signed via POA.
Clene Inc. (CLNN) director Matthew Kiernan was granted a stock option on 08/14/2025 for 3,720 shares of common stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $3.60 per share. The option vests immediately upon grant, is exercisable now, and expires on 08/13/2035. Following the grant, the reporting person beneficially owns 3,720 shares via direct ownership. The Form 4 was signed by a power of attorney, Jerome T. Miraglia, on 08/15/2025.
Clene Inc. director Alison Mosca was granted a stock option for 5,674 shares of common stock under the Clene Inc. Amended 2020 Stock Plan with an exercise price of $3.60 per share. The option was granted on 08/14/2025, vests immediately upon grant, is exercisable through 08/13/2035, and, if exercised, represents 5,674 shares of common stock. The Form 4 was signed via power of attorney on 08/15/2025.
Clene Inc. insider grant: Director Shalom Jacobovitz was granted a non-qualified stock option for 5,534 shares of Clene Inc. common stock on 08/14/2025 under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $3.60 per share. The option vests immediately upon grant and is exercisable through 08/13/2035. Following the grant, the reporting person beneficially owns 5,534 underlying shares and exercised price per share for reporting is shown as $0 (reflecting the reporting field for shares beneficially owned). The Form 4 was signed by a POA on 08/15/2025.
Clene Inc. (CLNN) reported a Section 16 Form 4 showing that director Jonathon Gay was granted a stock option on 08/14/2025 for 4,790 shares of common stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $3.60 per share. The filing states the options vest immediately upon grant.
The derivative instrument lists an expiration (or date referenced) of 08/13/2035. The Form 4 was signed by a power of attorney, Jerome T. Miraglia, on 08/15/2025. The report shows the acquisition was an option grant and indicates the number of underlying shares and exercise price but does not disclose total company holdings or percentage ownership after the grant.
Clene Inc. (CLNN) director Arjun J.J. Desai was granted a stock option for 4,278 shares on 08/14/2025 under the Clene Inc. Amended 2020 Stock Plan. The option has an exercise price of $3.60 per share, vests immediately upon grant, and is exercisable until its expiration on 08/13/2035. Following the grant, the reporting person beneficially owns 4,278 shares subject to this option, held directly. The Form 4 was filed as a single reporting person filing and signed by a power of attorney on 08/15/2025.